NASERUDDIN HÖTI, Ph.D.
Department of Urology, Johns Hopkins University School of Medicine
RESEARCH AND PROFESSIONAL EXPERIENCE
Prostate cancer affects one in six men and is the second leading cause of cancer death among men in the United States. Conventional therapies may lead to resistant cancer which is merely managed and not cured. Gene therapy using Adenoviral vectors have shown promise as a treatment strategy that can target both localized and metastatic prostate cancer.
The main mission of our group is to translate advances in imaging, oncology, and virology into innovative gene therapy based cancer therapeutics. Using molecular techniques to specifically re-target the viral vector to prostate cancer cells as well as shortening the life cycle of these viruses in order to invade and kill the tumor before they are cleared from the body.
FAMRI Young Clinical Scientist Award (YCSA) 2009-2011 Boston Massachusett USA
Wendy Will Case Cancer Award, CHICAGO, ILLINOIS 60603 (2010)
Short Term Max Planck Visiting Fellowship Award (2004) Dresden Germany
Merit scholarship in College (Top 15 students out of 100 students)
Full funded Ph.D Scholarship from the China Scholarship Council (CSC) and Ministry of Education Pakistan (MOE)
Full funded Merit Scholarship from the University of the Punjab Pakistan. (Distinction in M.Phil, Top the M.Phil session of 1999-2001)
Merit Scholarship in Undergraduate Level University of Agriculture Pakistan
Armoring CRAd with shRNA against p21/Waf-1---The next generation of oncolytic adenoviruses (ROI filed By Johns Hopkins School of Medicine)